Original news and analysis on international IP policy
The emphasis placed on the protection and enforcement of intellectual property for medicines in trade negotiations is ignoring the distorting effects of this emphasis, such as the lack of competition incentives which are key to reduce medicines prices, speakers on a panel of generic drug industries said at the World Trade Organization Public Forum last week.
A conference on clinical drug trials held today shed a harsh light on the availability and honesty of clinical trial reports. Many factors concur to possible distortion of results, speakers said, calling for more stringent obligations to provide all data for analysis. They also noted legislative efforts to tackle the issue. Speakers also pointed out a growing trend for pharmaceutical companies to conduct clinical trials in developing countries.
NEW YORK – Speakers at a side event to the United Nations General Assembly last week commended a new report on access to medicines prepared by a high-level panel hand-chosen by the UN secretary general as containing fresh ideas and the potential to bring change to a longstanding problem.
The World Health Organization today released the list of candidates to be the next director general of the UN health agency in Geneva. Of the six candidates, four are from the European region.
NEW YORK -- The membership of the United Nations today agreed a political declaration on antimicrobial resistance, elevating the global fight against overuse and misuse of antibiotics – and lack of new antibiotics – to the highest political level. The declaration struck by world leaders at the UN General Assembly in New York includes mention of separating medicine prices from the cost of research and development, and calls on the UN secretary-general to create an interagency coordination group. Now - as framed by many governments, intergovernmental organisations and nongovernmental representatives - attention moves to implementation of actions aimed at staving off this threat to humanity itself.
Antimicrobial resistance had in the last decades emerged as a health issue, but only in the last couple of years has there been an understanding that we are facing a “global societal challenge and threat.” On a day-to-day basis, people worldwide are said to be driving resistance across human health and agriculture.
It is essential that policy makers reform the systems for financing R&D, and de-link the costs of R&D from the prices of products, says James Love.
Governments are urged to do more to promote the development of desperately-needed new medicines, vaccines, and diagnostics at affordable prices and address the failures of research and development (R&D) in a new report by Médecins Sans Frontières.
The long-awaited report by the United Nations High Level Panel on Access to Medicines was released today, making many recommendations. The panel calls for countries to embrace the policy space available in the World Trade Organization intellectual property rules, and invest more in health. It also calls for negotiation of a binding international treaty on research and development, delinking prices from R&D costs, greater transparency in drug pricing, public health impact assessments in free trade agreements, and encouragement to better use international legal tools available to countries to ensure affordable medical products. And it lays out the path ahead, calling for several new bodies to be created to take recommendations forward. [Note: story is being continuously updated during the day, now adding industry response]
What levers need to be pulled to improve access to medicine worldwide? Jayasree K. Iyer, Executive Director of the Access to Medicines Index, shares ideas that she says would lead to more people accessing the medicine they need.
UNITAID, the drug financing mechanism, has put out an appeal calling for ideas on solutions to overcome intellectual property barriers that may be preventing progress in public health. The deadline for submissions is coming near.
Will an international instrument protecting genetic resources get in the way of the world’s preparedness to fend off the next influenza pandemic? This is one of the questions left open for a group of experts reviewing the World Health Organization Pandemic Influenza Preparedness (PIP) Framework. Meanwhile, one stakeholder is claiming to have been denied full and fair participation.